RT Journal Article
SR Electronic
T1 Campath-1H therapy in refractory ocular inflammatory disease
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 107
OP 109
DO 10.1136/bjo.84.1.107
VO 84
IS 1
A1 Andrew D Dick
A1 Paul Meyer
A1 Teife James
A1 John V Forrester
A1 Geoff Hale
A1 Herman Waldmann
A1 John D Isaacs
YR 2000
UL http://bjo.bmj.com/content/84/1/107.abstract
AB BACKGROUND Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation. METHODS 10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52. RESULTS AND DISCUSSION Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed.